Shattuck Labs, Inc. (NASDAQ:STTK) Receives $7.50 Consensus Price Target from Analysts

Shattuck Labs, Inc. (NASDAQ:STTK) has earned a consensus recommendation of “Moderate Buy” from the seven analysts that are presently covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $7.50.

Several research firms have recently commented on STTK. Leerink Partners began coverage on shares of Shattuck Labs in a research note on Monday, March 17th. They issued an “outperform” rating and a $4.00 price objective for the company. Needham & Company LLC reiterated a “hold” rating on shares of Shattuck Labs in a research note on Thursday, March 27th. Leerink Partnrs raised Shattuck Labs to a “strong-buy” rating in a report on Monday, March 17th. Finally, HC Wainwright reiterated a “neutral” rating on shares of Shattuck Labs in a research report on Thursday, March 27th.

Institutional Trading of Shattuck Labs

A number of large investors have recently made changes to their positions in STTK. Adage Capital Partners GP L.L.C. raised its stake in Shattuck Labs by 61.2% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 4,675,000 shares of the company’s stock valued at $5,657,000 after purchasing an additional 1,775,000 shares during the last quarter. 683 Capital Management LLC purchased a new stake in Shattuck Labs in the 4th quarter worth approximately $1,270,000. Prosight Management LP raised its holdings in Shattuck Labs by 15.1% in the 4th quarter. Prosight Management LP now owns 6,638,935 shares of the company’s stock valued at $8,033,000 after acquiring an additional 873,409 shares during the last quarter. Takeda Pharmaceutical Co. Ltd. purchased a new position in shares of Shattuck Labs during the 4th quarter worth $624,000. Finally, Bank of America Corp DE boosted its holdings in shares of Shattuck Labs by 135.0% during the fourth quarter. Bank of America Corp DE now owns 187,089 shares of the company’s stock worth $226,000 after purchasing an additional 107,491 shares during the last quarter. Institutional investors and hedge funds own 58.74% of the company’s stock.

Shattuck Labs Trading Up 4.8 %

Shares of STTK stock opened at $0.95 on Friday. Shattuck Labs has a twelve month low of $0.69 and a twelve month high of $11.76. The company’s 50-day moving average price is $1.18 and its 200-day moving average price is $1.24. The stock has a market cap of $45.50 million, a price-to-earnings ratio of -0.62 and a beta of 1.76.

Shattuck Labs (NASDAQ:STTK) last posted its earnings results on Thursday, March 27th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.01. Shattuck Labs had a negative net margin of 1,156.46% and a negative return on equity of 61.92%. As a group, equities research analysts predict that Shattuck Labs will post -1.48 EPS for the current year.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.